Landon C. Brown

659 total citations
29 papers, 372 citations indexed

About

Landon C. Brown is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Landon C. Brown has authored 29 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Landon C. Brown's work include Renal cell carcinoma treatment (11 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Prostate Cancer Treatment and Research (11 papers). Landon C. Brown is often cited by papers focused on Renal cell carcinoma treatment (11 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Prostate Cancer Treatment and Research (11 papers). Landon C. Brown collaborates with scholars based in United States, United Kingdom and Australia. Landon C. Brown's co-authors include Andrew J. Armstrong, Tian Zhang, Emmanuel S. Antonarakis, Jun Luo, Michael R. Harrison, Changxue Lu, Moshe Chaim Ornstein, Kunal Desai, Chester Kao and Ajjai Alva and has published in prestigious journals such as Journal of Clinical Oncology, Cancers and Journal for ImmunoTherapy of Cancer.

In The Last Decade

Landon C. Brown

25 papers receiving 369 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Landon C. Brown United States 12 252 195 108 89 49 29 372
Guzmán Alonso Spain 8 161 0.6× 177 0.9× 66 0.6× 75 0.8× 43 0.9× 34 313
Marco Brugia Italy 12 128 0.5× 218 1.1× 117 1.1× 100 1.1× 26 0.5× 31 354
Yuichi Tambo Japan 12 375 1.5× 319 1.6× 102 0.9× 66 0.7× 21 0.4× 42 483
Katherine A. Scilla United States 11 290 1.2× 363 1.9× 136 1.3× 162 1.8× 45 0.9× 25 583
Sarah Abou Alaiwi United States 12 207 0.8× 238 1.2× 127 1.2× 92 1.0× 33 0.7× 44 428
Yoshiro Nakahara Japan 12 255 1.0× 282 1.4× 55 0.5× 54 0.6× 44 0.9× 42 414
Zhaofei Pang China 14 169 0.7× 259 1.3× 152 1.4× 127 1.4× 67 1.4× 29 506
Maria Bassanelli Italy 10 326 1.3× 419 2.1× 99 0.9× 68 0.8× 57 1.2× 23 547
Kolette D. Fly United States 8 233 0.9× 179 0.9× 93 0.9× 73 0.8× 61 1.2× 15 460
Xiangying Meng China 11 166 0.7× 222 1.1× 34 0.3× 74 0.8× 51 1.0× 32 356

Countries citing papers authored by Landon C. Brown

Since Specialization
Citations

This map shows the geographic impact of Landon C. Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Landon C. Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Landon C. Brown more than expected).

Fields of papers citing papers by Landon C. Brown

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Landon C. Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Landon C. Brown. The network helps show where Landon C. Brown may publish in the future.

Co-authorship network of co-authors of Landon C. Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Landon C. Brown. A scholar is included among the top collaborators of Landon C. Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Landon C. Brown. Landon C. Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tran, Ben, Kevin D. Courtney, Alexandra Sokolova, et al.. (2025). A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy.. Journal of Clinical Oncology. 43(5_suppl).
2.
Burgess, Earle F., Claud Grigg, Danielle Boselli, et al.. (2025). Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial. Clinical Genitourinary Cancer. 23(2). 102302–102302.
3.
Brown, Landon C., Myra Robinson, Michael McCormack, et al.. (2024). Thrombosis Rates and Genetic Thrombophilia Risk Among Patients With Advanced Germ Cell Tumors Treated With Chemotherapy. Clinical Genitourinary Cancer. 22(3). 102086–102086. 1 indexed citations
4.
5.
Zhu, Jason, Chad Livasy, James T. Symanowski, et al.. (2023). Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer. Translational Andrology and Urology. 12(2). 228–240. 3 indexed citations
6.
Grigg, Claud, Wei Sha, Landon C. Brown, et al.. (2023). Association of tumor homologous recombination deficiency (HRD) score with immune checkpoint inhibitor benefit in metastatic clear cell renal cell carcinoma.. Journal of Clinical Oncology. 41(16_suppl). e16538–e16538.
7.
8.
Brown, Landon C., Susan Halabi, Jason A. Somarelli, et al.. (2022). A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate Cancer and Prostatic Diseases. 25(4). 762–769. 26 indexed citations
9.
Chen, Yu‐Wei, Matthew D. Tucker, Landon C. Brown, et al.. (2022). Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 40(16_suppl). 4527–4527. 1 indexed citations
10.
Abdallah, Mohamed, et al.. (2022). Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials. Annals of Hepatology. 27(6). 100738–100738. 17 indexed citations
11.
Brown, Landon C., Kunal Desai, Wei Wei, et al.. (2021). Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. Journal for ImmunoTherapy of Cancer. 9(9). e003281–e003281. 13 indexed citations
12.
Tucker, Matthew D., Landon C. Brown, Yu‐Wei Chen, et al.. (2021). Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomarker Research. 9(1). 80–80. 28 indexed citations
13.
Desai, Kunal, Landon C. Brown, Wei Wei, et al.. (2021). A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab. Targeted Oncology. 16(5). 633–642. 12 indexed citations
14.
Brown, Landon C., Matthew D. Tucker, Ramy Sedhom, et al.. (2021). LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. Journal for ImmunoTherapy of Cancer. 9(3). e001792–e001792. 73 indexed citations
15.
Brown, Landon C., Tian Zhang, & Daniel J. George. (2020). The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer. The Cancer Journal. 26(5). 376–381. 6 indexed citations
16.
Brown, Landon C., Kunal Desai, Tian Zhang, & Moshe Chaim Ornstein. (2020). The Immunotherapy Landscape in Renal Cell Carcinoma. BioDrugs. 34(6). 733–748. 27 indexed citations
17.
Brown, Landon C., Changxue Lu, Emmanuel S. Antonarakis, Jun Luo, & Andrew J. Armstrong. (2020). Androgen receptor variant-driven prostate cancer II: advances in clinical investigation. Prostate Cancer and Prostatic Diseases. 23(3). 367–380. 18 indexed citations
18.
Brown, Landon C., Ramy Sedhom, Eric Schwartz, et al.. (2020). Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.. Journal of Clinical Oncology. 38(15_suppl). 3007–3007. 5 indexed citations
19.
Brown, Landon C., Jason Zhu, Matthew Labriola, et al.. (2020). PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer. 18(6). 509–513. 1 indexed citations
20.
Brown, Landon C., et al.. (2017). The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy. American Journal of Nephrology. 45(4). 365–372. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guzmán Alonso Breakdown of academic impact, for papers by Marco Brugia Breakdown of academic impact, for papers by Yuichi Tambo Breakdown of academic impact, for papers by Katherine A. Scilla Breakdown of academic impact, for papers by Sarah Abou Alaiwi Breakdown of academic impact, for papers by Yoshiro Nakahara Breakdown of academic impact, for papers by Zhaofei Pang Breakdown of academic impact, for papers by Maria Bassanelli Breakdown of academic impact, for papers by Kolette D. Fly Breakdown of academic impact, for papers by Xiangying Meng
Rankless by CCL
2026